The P504S/AMACR monoclonal antibody is a highly specific reagent for the detection of alpha-methylacyl-CoA racemase (AMACR), also known by the prostate cancer biomarker designation P504S. AMACR is a mitochondrial and peroxisomal enzyme involved in the β-oxidation of branched-chain fatty acids and bile acid intermediates. It is overexpressed in prostatic adenocarcinoma, while being absent or minimally expressed in benign prostatic tissue, making it a valuable immunohistochemical marker in the diagnosis of prostate cancer. This monoclonal antibody recognizes a conserved epitope within the AMACR protein and has been validated for immunohistochemistry (IHC) on formalin-fixed paraffin-embedded (FFPE) tissue specimens. It produces a strong cytoplasmic staining pattern in malignant prostatic epithelial cells, with no significant staining in benign glands, basal cells, or stromal components. When used in combination with basal cell markers such as p63 or CK5/6, P504S significantly enhances diagnostic accuracy for distinguishing prostatic carcinoma from benign mimics in challenging cases. Beyond prostate pathology, AMACR is also expressed in several other malignancies including hepatocellular carcinoma, renal cell carcinoma, and colorectal adenocarcinoma, broadening its utility in tumor classification and cancer research
GRM349
GRM349 reacts human p504s/AMACR (Alpha-methylacyl-CoA racemase)
A peptide corresponding to the N-terminus of human Alpha-methylacyl-CoA racemase.
Immunohistochemistry (IHC) Western Blot (WB)
Human
None
Research Use Only
Stable for 1 Year at -20.0°C from date of receipt.
At Genebiosolution, our commitment lies in crafting cutting-edge solutions for researchers, clinicians, and diagnostic laboratories seeking excellence in immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). With a focus on quality, reliability, and accuracy, our products empower advancements in molecular diagnostics and research methodologies.
